NDA 218772 · Scienture
Arbli
Losartan Potassium · Oral
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Mar 13, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
425
92 Phase 3, 27 recruiting
FAERS reports
52,270
29,235 serious, 3,177 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Arbli as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Arbli as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )
What it is approved for
From the label in effect Oct 3, 2025.
Arbli is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) 1.1 Hypertension Arbli is indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to...
Mechanism: Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor found in many tissues, (e.g., vascular smooth muscle,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ARBLI · LOSARTAN POTASSIUM 10MG/ML · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Losartan" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Recurrent Stroke Prevention Clinical Outcome StudyPivotal-lookingStatus unknown
Biomedis International Ltd.Academic, hospital or other
NCT01198496 · 5,000 participants (planned) · Start Oct 2010 · Primary completion Dec 2017
Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone · For: Hypertension; Stroke; Blood Pressure
Sites: Shimotsuke, Japan
- Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00090259 · 3,834 participants · Start Dec 19, 2001 · Primary completion Mar 31, 2009
Drug: Losartan 50 mg; Losartan 150 mg · For: Heart Failure
- Prevention of Diabetes and HypertensionPivotal-lookingTerminated
Istituto Auxologico ItalianoAcademic, hospital or other
NCT00456963 · 3,000 participants (planned) · Start Sep 2007 · Primary completion Mar 2010
Drug: enalapril tablets; placebo tablets and 1 more · For: Diabetes Mellitus; Hypertension
Sites: Milan, Italy
- Hypertension Control Based on Home Blood PressurePivotal-lookingStatus unknown
Ministry of Health, Labour and Welfare, JapanGovernment (non-federal)
NCT00198562 · 2,600 participants (planned) · Start Apr 2000 · Primary completion Mar 2012
Drug: Amlodipine, Losartan · For: Hypertension
Sites: Suita, Japan
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CADPivotal-lookingActive, not recruiting
Cedars-Sinai Medical CenterAcademic, hospital or other
NCT03417388 · 2,476 participants · Start Feb 9, 2018 · Primary completion Feb 15, 2025
Drug: High dose potent statin; ACE-I (lisinopril) or ARB (losartan) and 1 more · For: Coronary Artery Disease
Sites: Mobile, Alabama; Gilbert, Arizona; Phoenix, Arizona · 81 sites in all
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue4,330
- diarrhoea3,322
- nausea2,981
- drug ineffective2,899
- dyspnoea2,762
- headache2,690
- dizziness2,520
- pain2,351
- cough2,055
- off label use1,990
- arthralgia1,969
- pruritus1,949
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 280 |
| 2005 | 365 |
| 2006 | 246 |
| 2007 | 382 |
| 2008 | 479 |
| 2009 | 424 |
| 2010 | 504 |
| 2011 | 1,586 |
| 2012 | 2,177 |
| 2013 | 902 |
| 2014 | 1,101 |
| 2015 | 1,793 |
| 2016 | 2,688 |
| 2017 | 2,976 |
| 2018 | 3,561 |
| 2019 | 3,936 |
| 2020 | 3,608 |
| 2021 | 3,782 |
| 2022 | 3,829 |
| 2023 | 3,922 |
| 2024 | 4,387 |
| 2025 | 5,135 |
| 2026 | 4,206 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Xie M, Tang T, Liang H · Clin Cardiol 2023 · Systematic Review, Network Meta-Analysis
- Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Brenner BM, Cooper ME, de Zeeuw D, et al. · N Engl J Med 2001 · Clinical Trial, Multicenter Study
- Losartan--a new antihypertensive.
· Drug Ther Bull 1995 · Clinical Trial, Randomized Controlled Trial
- Randomized placebo-controlled trial of losartan for pediatric NAFLD.
Vos MB, Van Natta ML, Blondet NM, et al. · Hepatology 2022 · Multicenter Study, Randomized Controlled Trial
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B, Devereux RB, Kjeldsen SE, et al. · Lancet 2002 · Clinical Trial, Comparative Study
- Angiotensin involvement in trauma processing-exploring candidate neurocognitive mechanisms of preventing post-traumatic stress symptoms.
Shkreli L, Woud ML, Ramsbottom R, et al. · Neuropsychopharmacology 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Scienture
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.